All posts by: Michael Zand

About Michael Zand

No Point in Testing Controversial Stem Cell Treatment, Italian Panel Says – Science Now

No Point in Testing Controversial Stem Cell Treatment, Italian Panel SaysScience NowROME—An expert panel that the Italian government asked to come up with a trial design for a controversial Italian stem cell therapy has thrown in the towel. The group, made up of top Italian scientists, has concluded that the treatment—designed by … …read more   &nbs… Continue reading

2013-09-12 NEWS

Pluristem Awarded Stem Cell Therapy Patent – Drug Discovery & Development

Pluristem Awarded Stem Cell Therapy PatentDrug Discovery & DevelopmentPluristem is studying a placenta-based stem cell therapy called PLX as a treatment for conditions including peripheral artery disease, or the narrowing of large arteries that supply blood to the extremities. In June, the Food and Drug Administration …Pluristem Therapeutics Inc. (PSTI): Celgene’s And Osiris’ IP Positions … Continue reading

2013-09-12 NEWS

Stem Cells Created In Living Mouse, Suggesting New Possibilities In … – Huffington Post

Stem Cells Created In Living Mouse, Suggesting New Possibilities In …Huffington PostLONDON (Reuters) – Scientists have succeeded in generating new stem cells in living mice and say their success opens up possibilities for the regeneration of damaged tissue in people with conditions ranging from heart failure to spinal cord injury. …read more   &nbs… Continue reading

2013-09-12 NEWS

Pluristem Therapeutics Inc. (PSTI): Celgene’s And Osiris’ IP Positions … – Seeking Alpha

Pluristem Therapeutics Inc. (PSTI): Celgene’s And Osiris’ IP Positions …Seeking AlphaIn 2002, Celgene purchased Anthrogenesis, a New Jersey company banking cord blood that developed a way to recover stem cells from placental tissue. Renamed Celgene Cellular Therapeutics, this subsidiary is now conducting a Phase I, multicenter … and more …read more   &nbs… Continue reading

2013-09-12 NEWS